-
Posted by
Two Blokes May 22, 2025 -
Filed in
Stock
-
8 views
Terumo continues to deliver solid financial results, with steady revenue growth and margin improvement, but share price performance has lagged the broader med-tech sector. The company's strengths lie in its established leadership in radial access products, strong BCT segment, and disciplined expansion into new growth areas like CDMO services. Management guides for healthy 7% constant currency growth and margin expansion, though U.S. tariffs could pose near-term profit headwinds.
